Journal of vascular surgery: official publication, the Society for Vascular Surgery [and] International Society for Cardiovascular Surgery, North American Chapter 04/2015; DOI:10.1016/j.jvs.2015.02.060 · 2.98 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: -Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk of clinical deterioration in surviving patients.
-We compared the angiotensin-neprilysin inhibitor LCZ696 (400 mg daily) with the angiotensinconverting enzyme inhibitor enalapril (20 mg daily) in 8399 patients with heart failure and reduced ejection fraction in a double-blind trial. The analyses focused on prespecified measures of nonfatal clinical deterioration. In comparison with the enalapril group, fewer LCZ696-treated patients required intensification of medical treatment for heart failure (520 versus 604; hazard ratio, 0.84; 95% confidence interval, 0.74-0.94; P=0.003) or an emergency department visit for worsening heart failure (hazard ratio, 0.66; 95% confidence interval, 0.52-0.85; P=0.001). The patients in the LCZ696 group had 23% fewer hospitalizations for worsening heart failure (851 versus 1079; P<0.001) and were less likely to require intensive care (768 versus 879; 18% rate reduction, P=0.005), to receive intravenous positive inotropic agents (31% risk reduction, P<0.001), and to have implantation of a heart failure device or cardiac transplantation (22% risk reduction, P=0.07). The reduction in heart failure hospitalization with LCZ696 was evident within the first 30 days after randomization. Worsening of symptom scores in surviving patients was consistently more common in the enalapril group. LCZ696 led to an early and sustained reduction in biomarkers of myocardial wall stress and injury (N-terminal pro-Btype natriuretic peptide and troponin) versus enalapril.
-Angiotensin-neprilysin inhibition prevents the clinical progression of surviving patients with heart failure more effectively than angiotensin-converting enzyme inhibition. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01035255.
[Show abstract][Hide abstract] ABSTRACT: Objectives: We aimed to investigate the role of oxidative
stress related with ischemia- reperfusion damage on the pathogenesis
of atrial fibrillation (AF) developing after coronary artery
bypass graft (CABG) surgery.
Study design: In our prospective, single-center study, 118 patients
who underwent elective isolated on-pump CABG surgery
were included. Patients were divided into two groups according
to the development of postoperative atrial fibrillation (POAF) as
Group 1: Patients who developed POAF, and Group 2: Patients
who remained in sinus rhythm. In addition to preoperative demographic,
laboratory, echocardiographic, intraoperative, and
postoperative clinical characteristics, levels of plasma total
oxidative status (TOS) after placement and removal of aortic
cross clamp (ACC) were compared between the two groups.
Predictors of POAF were also investigated by multivariate logistic
Results: A comparison of preoperative demographic, laboratory,
echocardiographic, and postoperative clinical characteristics
between the two groups showed that patients in Group 1
were significantly older (65.6±7.20 vs. 59.6±9.07, p<0.001), had
a lower hematocrit level (37.5±5.16 vs. 39.7±5.28; p=0.034),
and an enlarged left atrium diameter (39±0.45 vs. 3.6±0.48;
p=0.006). Changes in plasma TOS levels after placement and
removal of ACC were statistically significant in Group 1 [13 (8.6-
23), 30 (18.1-47.3); p=0.001 vs. 14 (8.8-22.2), 24 (21.4-42.7);
p=0.060]. Length of stay in the intensive care unit [3 (2-14) vs.
2 (1-58); p=0.001] and length of stay in hospital [7 (6-85) vs.
7 (5-58); p=0.001] were prolonged in Group 1. In multivariate
logistic regression analysis, aging (odds ratio (OR): 1.088, 95%
confidence interval (CI): 1.005-1.177; p=0.036), hematocrit level
(OR: 0.718, 95% CI: 0.538-0.958; p=0.025), pump temperature
(OR: 1.445, 95% CI: 1.059-1.972; p=0.020), and plasma TOS
level (OR: 1.040, 95% CI: 1.020-1.050; p=0.040) were found to
be independent predictors of POAF.
Conclusion: Ischemia-reperfusion damage related with ACC
placement may be an important factor on the pathogenesis of
POAF. Minimizing the oxidative stress occurring intraoperatively
should be targeted for preventing mortality and morbidity
Turk Kardiyoloji Dernegi arsivi: Turk Kardiyoloji Derneginin yayin organidir 07/2014; 2014;(42)5:419-425. DOI:10.5543/tkda.2014.84032
[Show abstract][Hide abstract] ABSTRACT: We determined the effect of 6-month rosuvastatin treatment on blood lipids, oxidative parameters, apolipoproteins, high-sensitivity C-reactive protein, lipoprotein(a), homocysteine, and glycated hemoglobin (HbA1c) in patients with metabolic syndrome (MetS). Healthy individuals (men aged >40 years and postmenopausal women) with a body mass index ≥30 (n = 100) who fulfilled the National Cholesterol Education Program Adult Treatment Panel III diagnostic criteria for MetS were included. Total cholesterol and low-density lipoprotein cholesterol (LDL-C) levels decreased (P < .0001). The change in LDL 1 to 3 subgroups was significant (P = .0007, P < .0001, and P = .006, respectively). Changes in LDL 4 to 7 subgroups were not significant. There was a beneficial effect on oxidized LDL, fibrinogen, homocysteine, and HbA1c. Rosuvastatin significantly increased high-density lipoprotein levels (P = .0003). The oxidant/antioxidant status and subclinical inflammatory state were also beneficially changed. Rosuvastatin had a significant beneficial effect on atherogenic dyslipidemia as well as on oxidative stress and inflammatory biomarkers in patients with MetS.
[Show abstract][Hide abstract] ABSTRACT: Resistin, which is derived from the gene of RSTN, belongs to a family of cysteine-rich secretory proteins called resistin-like molecules (RELMs). Increased serum resistin levels are associated with coronary artery disease (CAD) and the risk of cardiovascular death. Patients (n = 214) with an initial diagnosis of stable angina pectoris, unstable angina pectoris, and myocardial infarction without ST-segment elevation and referred to catheter laboratory for coronary angiography were enrolled in the study. We aimed to investigate the relationship between increased serum resistin level and CAD. The severity of CAD was calculated by the Gensini scoring system. In conclusion, we established a significant correlation between serum resistin levels and CAD (P = .010). Also, serum resistin levels correlated with the Gensini score that represents the severity of CAD angiographically (P = .010).
[Show abstract][Hide abstract] ABSTRACT: Background: Postoperative atrial fibrillation (AF) following cardiac surgery is associated with an increased risk of stroke, prolonged hospitalization, and increased costs. Statin therapy is associated with a lower incidence of postoperative AF. We aimed to compare the preventive effects of rosuvastatin and atorvastatin on postoperative AF. Methods: This study included 168 patients undergoing elective cardiac surgery with cardiopulmonary bypass. Patients were divided into 2 groups according to treatment of statin. Group 1 (n = 96) was patients receiving atorvastatin, and group 2 (n = 72) was patients receiving rosuvastatin. Postoperative electrocardiographs (ECGs) and telemetry strips were examined for AF within postoperative period during hospitalization. Results: The incidences of postoperative AF were 17.9% (n = 17) in group 1 and 22.2% (n = 16) in group 2 (P=.48). Left ventricular end-diastolic diameter (LVEDD) and ejection fraction (EF) were not different between groups. Incidence of diabetes, hypertension, hyperlipidemia, smoking, myocardial infarction in past medical history, family history of atherosclerosis, male sex, drug use, and perioperative features were similar between groups. Conclusions: The present study revealed that preoperative rosuvastatin or atorvastatin treatment did not have a different effect in preventing postoperative AF.
The Heart Surgery Forum 06/2013; 16(3). DOI:10.1532/HSF98.20121061 · 0.56 Impact Factor